Abstract
Atopic dermatitis (AD) is a common chronic-relapsing inflammatory skin disease, burdened by various comorbidities. AD most commonly occurs in children but may persist or present in adulthood becoming a lifelong condition. Therefore, AD requires an effective long-term treatment improving disease signs and symptoms but also of patients' quality of life (QoL). However continuous long-term use of most traditional AD immunosuppressive treatments is not recommended for safety reasons or insufficient efficacy data. Despite the available guidelines, there is still need for knowledge of AD long-term treatment, taking into account new disease measures and recent treatment options. Five Italian scientific societies implemented a joint consensus procedure to define the most appropriate clinical practice for the long-term management of adult moderate-severe AD. Through a modified Delphi procedure, consensus was reached by overall 51 Italian dermatologists and allergists (The Italian AD Study Group) experienced in the management of adult AD on 14 statements covering three AD areas of interest, namely diagnosis, definition of disease severity and clinimetrics, and a treat-to-target approach. This paper reports and discusses the agreed statements, which define disease and patient impact measures, therapeutic approach, and a treatment decision algorithm to support clinicians in the long-term management of adult patients with moderate-to-severe AD in their daily clinical practice.
Original language | English |
---|---|
Pages (from-to) | 1-12 |
Number of pages | 12 |
Journal | Italian Journal of Dermatology and Venereology |
Volume | 157 |
DOIs | |
Publication status | Published - 2022 |
Keywords
- Adult
- Allergists
- Asthma
- Biological products
- Child
- Consensus
- Dermatitis, Atopic
- Dermatitis, atopic
- Dermatologists
- Dermatology
- Diagnosis
- Dupilumab
- Hospitals
- Humans
- Quality of Life
- Venereology